According to GuruFocus list of 52-week highs, Covidien PLC, EQT Corp, Xilinx Inc. and Teva Pharmaceuticals Industries Ltd. have all reached their 52 week highs.
Covidien PLC (COV, Financial) Reached the 52-Week High of $71.95
Covidien PLC formerly known as Covidien Ltd. was incorporated in Bermuda in 2000 as a wholly-owned subsidiary of Tyco International Ltd. Covidien PLC has a market cap of $32.43 billion; its shares were traded at around $71.95 with a P/E ratio of 21.30 and P/S ratio of 3.25. The dividend yield of Covidien PLC stocks is 1.61%. Covidien PLC had an annual average earnings growth of 7.00% over the past 5 years.
Covidien PLC has released its first quarter 2014 results ended December 2013. First quarter net sales increased 3% year-over-year to $2.64 billion with operating income of $531 million versus $596 million a year ago. Diluted GAAP EPS were $0.87 versus $0.96 a year ago.
EQT Corp (EQT, Financial) Reached the 52-Week High of $102.29
EQT Corp is a Pennsylvania corporation formed in 2008 in connection with a holding company reorganization of the former Equitable Resources Inc. EQT Corp has a market cap of $15.43 billion; its shares were traded at around $102.29 with a P/E ratio of 48.10 and P/S ratio of 8.27. The dividend yield of EQT Corp stocks is 0.12%. EQT Corp had an annual average earnings growth of 11.10% over the past 10 years.
The company reported fourth quarter net income of $30.8 million and adjusted EBITDA of $36.3 million. Adjusted operating income grew 17% over last year to $30.8 million.
Xilinx Inc. (XLNX, Financial) Reached the 52-Week High of $52.20
Xilinx Inc. was founded and incorporated in California in February 1984. Xilinx Inc. has a market cap of $13.93 billion; its shares were traded at around $52.20 with a P/E ratio of 24.30 and P/S ratio of 6.43. The dividend yield of Xilinx Inc. stocks is 1.92%. Xilinx Inc. had an annual average earnings growth of 11.20% over the past 10 years. GuruFocus rated Xilinx Inc. the business predictability rank of 4-star.
Xilinx Inc. has announced its 2013 fiscal third quarter results – with sales up 15% to $587 million over the prior year quarter and net income of $176 million ($0.61 per share).
Sr. Vice President Steven L. Glaser sold 42,545 shares of XLNX stock on 02/27/2014 at the average price of $51.94. SVP WW Opertations Raja Petrakian sold 20,000 shares of XLNX stock on 02/27/2014 at the average price of $52.11.
Teva Pharmaceutical Industries Ltd. (TEVA, Financial) Reached the 52-Week High of $49.89
Teva Pharmaceutical Industries Ltd. develops, produces and markets generic, branded & OTC medicines. Teva Pharmaceutical Industries Ltd. has a market cap of $47.24 billion; its shares were traded at around $49.89 with a P/E ratio of 33.20 and P/S ratio of 2.09. The dividend yield of Teva Pharmaceutical Industries Ltd. stocks is 2.23%. Teva Pharmaceutical Industries Ltd. had an annual average earnings growth of 14.90% over the past 10 years. GuruFocus rated Teva Pharmaceutical Industries Ltd. the business predictability rank of 4.5-star.
Teva Pharmaceutical Industries has released its fourth quarter 2013 results. Total revenues were $5.4 billion for the quarter. Fourth quarter non-GAAP EPS were $1.42 and GAAP EPS were $0.45.
Check out the complete list of 52-Week Highs.
